Share This Article

Facebook LinkedIn
Twitter Reddit
Print Email
Pinterest Gmail
Yahoo
Money Morning
×
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • AI Investing
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
  • Retire
    • Income Investing Guide
    • Retirement Articles
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
    • Postcards
Login Archives Your Team About Us FAQ
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • AI Investing
    ×
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
    ×
  • Retire
    • Income Investing Guide
    • Retirement Articles
    ×
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
    • Postcards
    ×
  • Subscribe
Enter stock ticker or keyword
×
Join 100,000+ Like-Minded Investors Today
Twitter
Tags: Stocks
Stocks: VRX

Don't Be Fooled by Valeant Stock's 46% Rise This Month

By Ashley Moore, Associate Editor, Money Morning • May 19, 2017

Start the conversation

Leave a Reply Click here to cancel reply.

You must be logged in to post a comment.

Since the beginning of May, Valeant stock is up 46.7% and trading near $13.50. But we don't expect the rally to last.

Valeant StockThe current rally of Valeant Pharmaceuticals International Inc. (NYSE: VRX) is being driven by two things. While investors are viewing these two catalysts as bullish, they are really just temporary solutions.

After we review these short-term catalysts, we'll show you the long-term problems this stock is still facing...

Why Is Valeant Stock Rising?

The first thing is its earnings report on May 9. This is the first quarter in the last six that it has turned a profit. Plus, net income this quarter was $1.79 per share. Last year, the company lost $1.08 per share in the same quarter.

The earnings report also provided a bullish update on Valeant's debt repayment. At the end of 2016, the company had $29.8 billion in long-term debt. According to this last quarterly report, the company has repaid $1.3 billion of its debt.

The day the quarterly report was issued, the stock soared 24.1% to $12.08 a share.

The second catalyst for the stock this month is a new patent ruling.

On May 11, Valeant won its patent case concerning Xifaxan, the company's best-selling drug at about $1 billion in sales per year. There aren't many details since the file is sealed, but this does uphold the patent Valeant has for the irritable bowel syndrome with diarrhea (IBS-D) drug. The victory sent Valeant stock up 8.8% that day to close at $13.78 per share.

However, the stock is still down 6.35% year to date (YTD), and the company still has a lot to overcome...

Valeant Stock Is Still Trying to Overcome the Philidor Scandal

Back on Aug. 5, 2015, Valeant stock hit its all-time high of $257.53. By September of that year, Valeant executive Gary Tanner left the company amid allegations that the company's relationship with Philidor Rx Services LLC was potentially illegal. You see, Valeant was reportedly buying what it considered undervalued drugs and then raising the price by an average of 66%, according to a Deutsche Bank study. This rate hike was significantly larger than the rest of the industry, which averages a 22% hike.

Valeant ended the relationship with Philidor in October, but not before the U.S. Department of Justice opened an investigation into the business practices of the company.

On Nov. 17, 2016, Tanner and former Philidor CEO Andrew Davenport were charged with federal wire fraud and money laundering. And unfortunately that is not the end of the scandal for Valeant.

Must See: Get $45,000 Worth of Our Best Stock Research for Just Pennies a Day

Both have pled not guilty and are awaiting trial. Once the verdict is reached, Valeant can hopefully put this behind it. However, that time has not come.

All of this uncertainty has taken a toll on the company's revenue. Valeant's revenue growth has been shrinking for seven quarters. On average, revenue shrank by 11.5% over the last four quarters.

VRX stock

Until the company can resume revenue growth, we can't make a case to buy Valeant stock. The shrinking revenue shows it still has not fully recovered from the Philidor scandal.

But we did find a way to profit 90% on Valeant's downfall. Here's how...

We Banked 90% on Valeant's Plummet

Here Are 10 “One-Click” Ways to Earn 10% or Better on Your Money Every Quarter

Appreciation is great, but it’s possible to get even more out of the shares you own. A lot more: you can easily beat inflation and collect regular income to spare. There are no complicated trades to put on, no high-level options clearances necessary. In fact, you can do this with a couple of mouse clicks – passive income redefined. Click here for the report…

Claim My Free Report

Subscribe
Login
Notify of
guest

guest

0 Comments
Inline Feedbacks
View all comments


Latest News

September 25, 2023 • By Tom Gentile

This Little-Known Secret Can Help You Perfectly Time Your Next Trade

September 25, 2023 • By Shah Gilani

earnings
This Stock Is Yielding Over Double the Inflation Rate Right Now

September 22, 2023 • By Shah Gilani

earnings
Why the Fed's "Higher for Longer" Message on Interest Rates is Bogus
Trending Stories
ABOUT MONEY MORNING

Money Morning gives you access to a team of market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.

QUICK LINKS
About Us COVID-19 Announcements How Money Morning Works FAQs Contact Us Search Article Archive Forgot Username/Password Archives Profit Academy Research Your Team Videos Text Messaging Terms of Use
FREE NEWSLETTERS
Total Wealth Research Power Profit Trades Penny Hawk Midday Momentum
PREMIUM SERVICES
Money Map Press Home Money Map Report Fast Fortune Club Weekly Cash Clock Microcurrency Trader Hyperdrive Portfolio Rocket Wealth Initiative Quantum Data Profits Flashpoint Trader Darknet Alpha Accelerators Brutus Alerts Resource Traders Alliance L.A.U.N.C.H. Investor Rob Roy Trader Long-Term Equity Profits

© 2023 Money Morning All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning.

Address: 1125 N Charles St. | Baltimore, MD, 21201 | USA | Phone: 888.384.8339 | Disclaimer | Sitemap | Privacy Policy | Whitelist Us | Do Not Sell or Share My Personal Information

wpDiscuz